- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | - | ASX | ||
| Di | AROA BIOSURGERY LIMITED: Symphony - Outpatient Reimbursement Update | - | ASX | ||
| 09.07. | AROA BIOSURGERY LIMITED: Resignation of CFO and Joint Company Secretary | - | ASX | ||
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 30.06. | AROA BIOSURGERY LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 30.06. | AROA BIOSURGERY LIMITED: Annual Report to Shareholders | - | ASX | ||
| 29.06. | AROA BIOSURGERY LIMITED: Change of Director's Interest Notice - JD | - | ASX | ||
| 24.06. | AROA BIOSURGERY LIMITED: Notice of AGM Date and Director Nomination Closing Date | - | ASX | ||
| 27.05. | AROA BIOSURGERY LIMITED: Change in substantial holding | - | ASX | ||
| 26.05. | Biocurious: Aroa brings a touch of 'magic' to the US$3 billion woundcare sector | 1 | Stockhead | ||
| 26.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation - Correction | - | ASX | ||
| 26.05. | Aroa Biosurgery Sets Ambitious FY27 Targets after Exceeding FY26 Guidance | 2 | smallcaps.com.au | ||
| 25.05. | AROA BIOSURGERY LIMITED: FY26 Full Year Results Presentation | - | ASX | ||
| 25.05. | AROA BIOSURGERY LIMITED: FY26 Appendix 4E and Full Year Results | - | ASX | ||
| 18.05. | AROA BIOSURGERY LIMITED: Notification of Full Year Results Webinar | - | ASX | ||
| 30.04. | Health Check: Investors say "not baa-d" as Aroa smashes earnings expectations out of the paddock | 3 | Stockhead | ||
| 29.04. | AROA BIOSURGERY LIMITED: ARX FY26 Preliminary Results | - | ASX | ||
| 10.04. | AROA BIOSURGERY LIMITED: Application for quotation of securities - ARX | - | ASX | ||
| 09.04. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | - | ASX | ||
| 30.03. | Aroa Biosurgery's Symphony Shows Positive Preliminary Results For Diabetic Foot Ulcers | 2 | RTTNews | ||
| 30.03. | AROA Biosurgery Completes Randomised Controlled Trial for Symphony; Preliminary Read-Out indicates Primary Endpoint Met | 369 | PR Newswire | AUCKLAND, New Zealand, March 29, 2026 /PRNewswire/ -- Aroa Biosurgery Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,05 | -0,31 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen | |
| EVOTEC | 3,440 | -0,64 % | Märkte am Morgen: Öl, ExxonMobil, Gold, Nvidia, SanDisk, SAP, Traton, Bayer, Evotec, Salzgitter | Der DAX hat sich zum Wochenauftakt überraschend stabil gezeigt. Und das trotz der zunehmenden Spannungen im Nahen Osten. Heute deutet kurz vor Handelsstart vieles darauf hin, dass sich diesmal die Bären... ► Artikel lesen | |
| MODERNA | 54,08 | +0,11 % | Arbutus Biopharma Corporation: Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders | Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech... ► Artikel lesen | |
| NOVAVAX | 7,130 | -0,83 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,460 | +0,41 % | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma berichtet über das erste Halbjahr 2026 und positiven Geschäftsverlauf | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Halbjahresbericht
Heidelberg Pharma berichtet über das erste Halbjahr 2026 und positiven Geschäftsverlauf
15.07.2026 / 07:11... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,971 | -0,46 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| BIOMARIN PHARMACEUTICAL | 52,12 | 0,00 % | BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia | Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth... ► Artikel lesen | |
| IBIO | 1,301 | +7,43 % | iBio, Inc. - 8-K, Current Report | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Announces Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 4,180 | +4,76 % | Arbutus, Genevant File International Lawsuits Against Pfizer, BioNTech | NEW YORK CITY (dpa-AFX) - Arbutus Biopharma (ABUS), and its licensee, Genevant Sciences - a unit of Roivant Sciences (ROIV)), announced the filing of three international lawsuits seeking to... ► Artikel lesen | |
| LAKEFRONT BIOTHERAPEUTICS | 25,700 | -2,06 % | Lakefront Biotherapeutics: Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi | Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,540 | +1,20 % | Cellectar publishes phase 1 data on multiple myeloma treatment | ||
| CYTODYN | 0,198 | +3,12 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| TRAWS PHARMA | 0,670 | -0,12 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen |
Das Unternehmen AROA BIOSURGERY LIMITED kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.